Smedeland 26B
Glostrup 2600
Denmark
45 70 70 52 25
https://www.saniona.com
Settore/i:
Settore:
Impiegati a tempo pieno: 23
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Jorgen Drejer Ph.D. | Founder, Chairman & Deputy CEO | 3,28M | N/D | 1955 |
Mr. Thomas Feldthus M.Sc., MBA | Co-Founder & CEO | 2,32M | N/D | 1960 |
Ms. Anita Milland B.Com. | Chief Financial Officer | N/D | N/D | 1968 |
Mr. Karin Sandager Nielsen Ph.D. | Chief Scientific Officer | N/D | N/D | 1970 |
Mr. Palle Christophersen M.S., Ph.D. | Executive Vice President of Research | 1,38M | N/D | 1958 |
Mr. Janus Schreiber Larsen | Chief Development Officer | N/D | N/D | 1972 |
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which has completed Phase 1 clinical stage for neuropathic pain conditions; SAN903 for inflammatory and fibrotic disorders; and SAN2219, that is in preclinical stage for treatment of epilepsy. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS; and research collaboration with AstronauTx to identify new treatments for Alzheimer's disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
L'ISS Governance QualityScore di Saniona AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.